• Publications
  • Influence
ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer.
International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG).
The proposed system for defining and recording perioperative complications associated with esophagectomy provides an infrastructure to standardize international data collection and facilitate future comparative studies and quality improvement projects.
The Number of Lymph Nodes Removed Predicts Survival in Esophageal Cancer: An International Study on the Impact of Extent of Surgical Resection
The number of lymph nodes removed is an independent predictor of survival after esophagectomy for cancer, and to maximize this survival benefit a minimum of 23 regional lymph nodes must be removed.
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.
An international, multidisciplinary, systematic, evidence-based review of different management strategies for patients with Barrett's esophagus and dysplasia or early-stage EA and developed a data-sifting platform and used the Delphi process to create evidence- based consensus statements.
Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after
Integrated PET-CT yielded a better result than that obtained in previous studies with side-by-side PET and CT images, but postinduction remediastinoscopy had a disappointing sensitivity because of adhesions and fibrosis.
Lung donor selection and management.
The current evidence from the literature is updated to identify and select potential lung donors and to manage cadaveric donors to maximally increase the organ yield for lung transplantation.
Optimum Lymphadenectomy for Esophageal Cancer
Greater extent of lymphadenectomy was associated with increased survival for all patients with esophageal cancer except at the extremes (TisN0M0 and ≥7 regional lymph nodes positive for cancer) and well-differentiated pN 0M0 cancer.
Minimally invasive esophagectomy for cancer.
Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial.
Tumor size was found in univariate analysis to be a significant risk factor for local recurrence in the breast-conserving therapy group but not in the mastectomy group, and Measurements of quality of life and cosmesis show a clear benefit for the Breast-conserve therapy group.